<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03725865</url>
  </required_header>
  <id_info>
    <org_study_id>iNSC-81NK-01</org_study_id>
    <nct_id>NCT03725865</nct_id>
  </id_info>
  <brief_title>A Clinical Study of iNSC Intervent Cerebral Hemorrhagic Stroke</brief_title>
  <official_title>A Clinical Study of Intracerebral Transplantation of Human Peripheral Blood Derived Induced Neural Stem Cells for Cerebral Hemorrhagic Stroke</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allife Medical Science and Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allife Medical Science and Technology Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single centre、single arm、open-label，to investigate the safety and efficacy of
      induction of neural stem cells transplantation in the brain
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2019</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Treatment Emergent AE</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Stroke, Ischemic</condition>
  <arm_group>
    <arm_group_label>iNSC treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Induction of neural stem cells</intervention_name>
    <description>Brain injection iNSC</description>
    <arm_group_label>iNSC treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Have the ability to understand the requirements of the study, provide written informed
             consent, and comply with the study procedures.

          2. Men and women 30-65 years old.

          3. Women must have a negative serum pregnancy test, gestation age women practice an
             acceptable method of contraception.

          4. At least 12 months but no more than 60 months from time of hemorrhagic stroke, with a
             motor neurological deficit.

          5. Documented history of single hemorrhagic stroke in subcortical region of MCA or
             lenticulostriate artery with or without cortical involvement, with correlated findings
             by MRI.

          6. Modified Rankin Score of 2, 3 or 4.

          7. FMMS score of 55 or less, two evaluations at approximately 3 weeks apart prior to
             surgery with less than +/- 5 point change in the FMMS.

          8. Two evaluations at approximately 3 weeks apart prior to surgery with less than +/- 4
             point change in the NIHSS.

          9. Able and willing to undergo post-physical therapy/rehabilitation.

        Exclusion Criteria:

          1. Any disabling psychological or psychiatric disorders which may confound the study.

          2. History of more than one hemorrhagic stroke.

          3. History of another major neurological disease or injury.

          4. Cerebral soften lesion size &gt;5cm in any one measurement.

          5. Myocardial infarction within the prior 3 months.

          6. History of seizures or current use of antiepileptic medication.

          7. History of peripheral nerve surgery, including Selective Dorsal Rhizotomy and
             Contralateral Seventh Cervical Nerve Transfer.

          8. Receipt of any investigational drug or device within 30 days.

          9. Receipt of any cell infusion other than blood transfusion.

         10. Any concomitant medical disease or condition noted below:

               1. Coagulopathy.

               2. Active or history of malignancy.

               3. Primary or secondary immune deficiency.

               4. Persistent MRI artifact or unable to undergo MRI.

         11. Any condition that the Investigator or primary physician feels may interfere with
             participation in the study or may endanger the subject.

         12. Any condition that the surgeon feels may pose complications for the surgery.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2018</verification_date>
  <study_first_submitted>October 29, 2018</study_first_submitted>
  <study_first_submitted_qc>October 29, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 31, 2018</study_first_posted>
  <last_update_submitted>October 29, 2018</last_update_submitted>
  <last_update_submitted_qc>October 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

